Show simple item record

dc.contributor.authorMontes, M
dc.contributor.authorNelson, M
dc.contributor.authorGirard, PM
dc.contributor.authorSasadeusz, J
dc.contributor.authorHorban, A
dc.contributor.authorGrinsztejn, B
dc.contributor.authorZakharova, N
dc.contributor.authorRivero, A
dc.contributor.authorLathouwers, E
dc.contributor.authorJanssen, K
dc.contributor.authorOuwerkerk-Mahadevan, S
dc.contributor.authorWitek, J
dc.date.accessioned2020-12-18T03:32:27Z
dc.date.available2020-12-18T03:32:27Z
dc.date.issued2014-11-01
dc.identifierpii: 19626
dc.identifier.citationMontes, M., Nelson, M., Girard, P. M., Sasadeusz, J., Horban, A., Grinsztejn, B., Zakharova, N., Rivero, A., Lathouwers, E., Janssen, K., Ouwerkerk-Mahadevan, S. & Witek, J. (2014). Telaprevir combination therapy in HCV/HIV co-infected patients (INSIGHT study): sustained virologic response at 12 weeks final analysis. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 17 (4 Suppl 3), pp.90-91. https://doi.org/10.7448/IAS.17.4.19626.
dc.identifier.issn1758-2652
dc.identifier.urihttp://hdl.handle.net/11343/255812
dc.description.abstractINTRODUCTION: We report the SVR12 final analysis of a phase 3 study of telaprevir in combination with peginterferon (P)/ribavirin (R) in HCV-genotype 1, treatment-naïve and -experienced patients with HCV/HIV co-infection (INSIGHT). MATERIALS AND METHODS: Patients receiving stable, suppressive HIV antiretroviral (ARV) therapy, containing atazanavir/ritonavir, efavirenz, darunavir/ritonavir, raltegravir, etravirine or rilpivirine, received telaprevir 750 mg q8h (1125 mg q8h if on efavirenz) plus P (180 µg once-weekly) and R (800 mg/day) for 12 weeks, followed by an additional 12 weeks (non-cirrhotic HCV treatment-naïve and relapse patients with extended rapid viral response [eRVR]) or 36 weeks (all others) of PR alone. Analysis was performed when all patients had completed the follow-up visit of 12 weeks after last planned dose. RESULTS: One hundred sixty-two patients were enrolled and treated (65 efavirenz, 59 atazanavir/ritonavir, 17 darunavir/ritonavir, 17 raltegravir, 4 etravirine). Mean age was 45 years, 78% were male, 92% were Caucasian; mean CD4 count was 687 cells/mm(3). Sixty four patients (40%) were HCV treatment-naïve and 98 (60%) were treatment experienced (29 relapsers, 18 partial responders and 51 null responders). 64% were subtype 1a. 30% had bridging fibrosis (17%) or cirrhosis (13%). 19% of patients discontinued telaprevir, including 9% due to an adverse event (AE), 8% reaching a virologic endpoint and 2% for other reasons (non compliance or not defined). Treatment responses are shown in Table 1. There were no HIV RNA breakthroughs. Most frequently reported (≥20% patients) AEs were pruritus 43%; fatigue 27%; rash 34%, anorectal events 30% and influenza-like illness (25%). Anemia was reported in 15% of patients; grade ≥3 haemoglobin decrease occurred in 2.5% of patients. 6% of patients experienced serious AEs. CONCLUSIONS: In this phase 3 study of HIV-infected, HCV treatment-naïve and -experienced patients, 49% achieved eRVR and 57% reached SVR12. In patients with an eRVR, SVR12 rates were >80%, irrespective of prior treatment history.
dc.languageEnglish
dc.publisherJOHN WILEY & SONS LTD
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titleTelaprevir combination therapy in HCV/HIV co-infected patients (INSIGHT study): sustained virologic response at 12 weeks final analysis
dc.typeJournal Article
dc.identifier.doi10.7448/IAS.17.4.19626
melbourne.affiliation.departmentDoherty Institute
melbourne.source.titleJournal of the International AIDS Society
melbourne.source.volume17
melbourne.source.issue4 Suppl 3
melbourne.source.pages90-91
dc.rights.licenseCC BY
melbourne.elementsid1306301
melbourne.openaccess.pmchttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC4224845
melbourne.contributor.authorSasadeusz, Joseph
dc.identifier.eissn1758-2652
melbourne.event.locationSwitzerland
melbourne.accessrightsOpen Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record